AGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AGENUS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.18+0.14 (+2.32%)
Close on Oct 19, 2026
- Market cap
- $255.47M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$2.30 (+59.28%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
AGENUS INC grew revenue 30.5% to $132.69M over the twelve months to Jun 30, 2026. Free cash flow was -$98.50M.
Revenue
$132.69M
+30.5% vs. a year earlier
Operating income
$36.20M
TTM Q2 2026
Free cash flow
-$98.50M
TTM Q2 2026
EPS, diluted
$0.00
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $255.47M
- P/E ratio
- –
- Price to sales
- 1.93
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -38.56%
Fundamentals
- Revenue
- $132.69M
- EPS, diluted
- $0.00
- Free cash flow
- -$98.50M
- Book value per share
- -$4.82
- Diluted shares
- 41M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$132.69M+30.5% YoY
Gross profit
$132.05M+30.7% YoY
Operating income
$36.20M
Net income
–
EPS, diluted
–
Free cash flow
-$98.50M
Reported periodTrailing twelve months